Zeitschrift für klinische Krebsstudien

Early Use of Next Generation Sequencing Provided Alternative Treatment Options to 32.24% of Advanced Stage Cancer Patients (Avoiding or Delaying Chemotherapy)-Retrospective Study in Solid Tumors at Beverly Hills Cancer Center

Abstract

Nathan Gabayan, Ali Muhammad

Our providers’ continuous efforts to obtain Next-Generation Sequencing for their cancer patients as early as possible followed by appropriately matched therapy has provided new therapeutic options to our patients. This retrospective study included 95 solid tumor patients who were genotyped with the FDA-approved Guardant360 CDx liquid biopsy that provides comprehensive genomic results from a blood draw in seven days X (https:// guardanthealth.com/media/). Our oncologists use it on regular basis for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), across all solid cancers